The changing roles of steroid nuclear receptors with prostate cancer progression

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages

  Savoy, Rosalinda M ^a,c   Ghosh, Paramita M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Androgen receptor; Estrogen receptor ; Hormone na ve; Prostate cancer; Serine 210 phosphorylation

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; ESTROGEN THERAPY; HORMONE BLOOD LEVEL; HUMAN; NOTE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR Β; HORMONE-NAÏVE; PROSTATE CANCER; SERINE 210 PHOSPHORYLATION;

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84882797893     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0193     Document Type: Note

References (9)

1. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM, Thompson TC & Rowley D 2004 Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Research 64 6082-6090. (doi:10.1158/0008-5472.CAN-04-0838)
2. Bardin A, Boulle N, Lazennec G, Vignon F & Pujol P 2004 Loss of ERb expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer 11 537-551. (doi:10.1677/erc.1.00800)
3. Horvath LG,HenshallSM, Lee CS,HeadDR,QuinnDI,Makela S,DelpradoW, Golovsky D, Brenner PC, O'Neill G et al. 2001 Frequent loss of estrogen receptor-b expression in prostate cancer. Cancer Research 61 5331-5335.
4. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S & Ghosh PM 2004 Phosphorylation of Akt (Ser473) is an excellentpredictor of poor clinical outcome in prostate cancer. Cancer Research 64 5232-5236. (doi:10.1158/0008-5472.CAN-04-0272)
5. Lin HK, Yeh S, Kang HY & Chang C 2001 Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. PNAS 98 7200-7205. (doi:10.1073/pnas.121173298)
6. Minutolo F,Macchia M, Katzenellenbogen BS & Katzenellenbogen JA 2011 Estrogen receptor b ligands: recent advances and biomedical applications. Medicinal Research Reviews 31 364-442. (doi:10.1002/med.20186)
7. Oh WK 2002 The evolving role of estrogen therapy in prostate cancer. Clinical Prostate Cancer 1 81-89. (doi:10.3816/CGC.2002.n.009)
8. Pravettoni A, Mornati O, Martini PG, Marino M, Colciago A, Celotti F, Motta M & Negri-Cesi P 2007 Estrogen receptor b (ERb) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Molecular and Cellular Endocrinology 263 46-54. (doi:10.1016/j.mce.2006.08.008)
9. Zellweger T, Sturm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L & Ruiz C 2013 Estrogen receptor b expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocrine-Related Cancer 20 403-413. (doi:10.1530/ERC-12-0402)